Clinical Trial Update: Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating bortezomib, selinexor, and dexamethasone in relapsed/refractory multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Velcade (bortezomib)
• XPOVIO (selinexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2021-07-08